Continuous Chest Wall Vibration in COPD Rehabilitation

February 4, 2020 updated by: Riccardo Buraschi, Fondazione Don Carlo Gnocchi Onlus

Effects of Continuous Chest Wall Vibration on Dyspnea and Exercise Tolerance in COPD Patients

Dyspnea, the sensation of breathing discomfort or shortness of breath, is one of the main symptoms for patients affected by Chronic Obstructive Pulmonary Disease (COPD), particularly during exercise. Previous study show that chest wall vibration decrease dyspnea in COPD patients and precisely when applied during the inspiration phase, called "in-phase vibration" (IPV) which provide vibration directly on intercostal muscles. These findings have been obtained in laboratory context and the intercostals muscles vibration has been tested only in single phases of breathing, during inspiration with IPV and during exhalation with out-of-phase vibration (OPV). None study has evaluated the effect of a continuous chest wall vibration (CCWV), namely muscles vibration during the whole cycle of breathing, on dyspnea in patients with COPD in a clinical context. Continuous high frequency vibration has been proven to reduce myoelectrical manifestation of fatigue, probably modifying the centrally driven motor unit recruitment hierarchy, in healthy subjects.

Moreover, CCWV is a modality of provide vibration more suitable and cost-effective in a clinical context than single-phases vibration that requires specific instruments for the detection of breathing phases and the coupling with vibration device.

On these bases, the investigators hypothesized that CCWV at high frequency, applied during a cycle ergometer training program, could decrease dyspnea and enhance the exercise tolerance in COPD patients. Therefore, the aim of this study is to evaluate the effects of high frequency CCWV on dyspnea and exercise tolerance in patients with COPD patients compared to usual care and to sham intervention.

Study Overview

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Brescia
      • Rovato, Brescia, Italy, 25038
        • Fondazione Don Carlo Gnocchi Onlus - Centro Ettore Spalenza

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

- COPD diagnosis (GOLD stage: 2-3-4)

Exclusion Criteria:

  • Restrictive lung disease
  • Active pulmonary infection
  • Pulmonary embolism (less than 3 months)
  • Pneumotorax
  • Thoracic/abdominal operation (less than 3 months)
  • Myocardial infarction (less than 6 months)
  • Congestive heart failure/ heart failure/ right heart failure
  • Angina/severe angina
  • Incapability of perform the cycle ergometer training (e.g. orthopaedic or urogenital conditions)
  • Incapability to understand the intructions required to carry out the tests and assessments planned

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Control group
Cycle ergometer training program: 2 minutes warm-up at no load, 20 minutes at 60% of peak work (PW) calculated by stress-test or at 50% of PW calculated according to Luxton equation (PW = 103.217 + (30.50 X gender) + (-1.613 X age) + (0.002 X 6MWW [m kg -1 ]). The progression of the workloads is calculated according to the BORG Dyspnea and Fatigue Scale (Borg D and F < 5: 10W increase; Borg D and/or F between 5 e 6: maintain same workload; Borg D and / or > 6: 10W decrease) Patient tailored airway clearance program guided by an experienced respiratory physical therapist, which could includes active cycle of breathing technique (ACBT), forced expiratory technique (FET), ELTGOL (slow expiration with glottis open in the lateral position) and PEP techniques (positive expiratory pressure).
Already in arm/group descriptions
Already in arm/group descriptions
EXPERIMENTAL: Experimental group
Cycle ergometer training program plus application of vibration therapy. The vibration is provided at 150Hz via 4 effectors applied bilaterally at the second or third interspaces in the parasternal region of the upper chest wall and at the seventh to ninth interspaces anterior to the midaxillary line in the lower chest wall.
Already in arm/group descriptions
Already in arm/group descriptions
Already in arm/group descriptions
SHAM_COMPARATOR: Sham intervention group
Cycle ergometer training program plus application of sham vibration therapy: 4 effectors on chest-wall at same position of vibration therapy, the device that produces vibration is switched on, producing the typical noise and vibration is emitted by effectors not placed on the patient but left in place on the device.
Already in arm/group descriptions
Already in arm/group descriptions
Already in arm/group descriptions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of Dyspnea
Time Frame: Change from Baseline Barthel Index based on dyspnea at 4 weeks
Barthel Index based on dyspnea. The scale measures the level of dyspnea perceived in performing basic daily living activities, Range: 0 - 100 Higher values represent a worse outcome
Change from Baseline Barthel Index based on dyspnea at 4 weeks
Change of exercise tolerance
Time Frame: Change from Baseline exercise tolerance at 4 weeks

Six Minutes Walking Test. This test assesses distance walked over 6 minutes as a sub-maximal test of aerobic capacity/endurance.

Higher values represent a better outcome

Change from Baseline exercise tolerance at 4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of respiratory muscles strength
Time Frame: Change from Baseline respiratory muscles strength at 4 weeks

Maximum inspiratory pressure / Minimum expiratory pressure.

Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) are global measures of maximal strength of respiratory muscles and they are respectively the greater pressure which may be generated during maximal inspiration and expiration against an occluded airway. The way to measure maximal respiratory pressures is very simple, using a hand-held mouth pressure meter in cmH2O.

Higher values represent a better outcome

Change from Baseline respiratory muscles strength at 4 weeks
Change of Risk of death
Time Frame: Change from Baseline risk of death at 4 weeks

BODE Index.

Is a multidimensional 10-point grading system that predicts the risk of death from any cause and from respiratory causes among patients with COPD. It is composed by subscales, combined to compute a total score as follows:

FEV1 (% of predicted): 0 (≥65); 1 (50-64); 2 (36-49); 3 (≤35). Distance walked in 6 minutes (m): 0 (≥350); 1 (250-349); 2 150-249); 3 (≤149). MMRC dyspnea scale:0 (0-1); 1 (2); 2 (3); 3 (4). Body-mass Index: 0 (>21); 1 (≤21).

Range: 0-10 Higher scores indicate a worse outcome (higher risk of death)

Change from Baseline risk of death at 4 weeks
Change of Health-related quality of life
Time Frame: Change from Baseline health-related quality at 4 weeks

Saint George Respiratory Questionnaire. Is a self-reported, disease-specific, health-related quality of life questionnaire.

Range: 0 (no health impairment) - 100 (maximum health impairment).

Higher values represent a worse outcome

Change from Baseline health-related quality at 4 weeks
Change of Sympatho-vagal balance
Time Frame: Change from Baseline sympatho-vagal balance at 2 weeks and at 4 weeks
Heart Rate Variability
Change from Baseline sympatho-vagal balance at 2 weeks and at 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 12, 2018

Primary Completion (ACTUAL)

September 30, 2019

Study Completion (ACTUAL)

September 30, 2019

Study Registration Dates

First Submitted

August 17, 2018

First Submitted That Met QC Criteria

August 22, 2018

First Posted (ACTUAL)

August 23, 2018

Study Record Updates

Last Update Posted (ACTUAL)

February 5, 2020

Last Update Submitted That Met QC Criteria

February 4, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • Vibra_COPD_FDG

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on Cycle ergometer training

3
Subscribe